Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Correct on core indication and recommended adult dose; however, several administration/timing instructions (meals, missed dose handling) and population-specific dosing concepts (kidney/liver) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
IBSRELA (tenapanor) is taken by mouth as a fixed dose of 50 mg twice daily (morning and evening).
Supported by FDA label section 2 DOSAGE AND ADMINISTRATION (50 mg orally twice daily). Morning/evening timing specifics are not provided in the excerpt, but the twice-daily dosing is supported.
Standard dosing of IBSRELA is 50 mg twice daily.
Supported by FDA label section 2 DOSAGE AND ADMINISTRATION (recommended dosage is 50 mg orally twice daily).
Taking more than the prescribed dose of IBSRELA can increase the risk of gastrointestinal side effects, especially diarrhea.
Supported by FDA label section 10 OVERDOSAGE (overdose may result in GI adverse effects such as diarrhea).
Unsupported Statements
IBSRELA is typically taken with meals.
Not supported by the provided FDA label excerpts.
IBSRELA is designed to work in the gut with food intake.
Not supported by the provided FDA label excerpts.
If a dose of IBSRELA is missed, it should be taken when remembered unless it is close to the next scheduled dose.
Missed-dose instructions are not present in the provided FDA label excerpts.
If a dose of IBSRELA is missed, two doses should not be taken at once to make up for a missed dose.
Missed-dose instructions are not present in the provided FDA label excerpts.
If side effects occur, clinicians may recommend dose changes or stopping therapy depending on severity and tolerability.
Label excerpt (5.2 Diarrhea) specifies suspending dosing and rehydration for severe diarrhea, but does not generally state that clinicians may adjust dose or stop therapy based on severity/tolerability.
Dosing of IBSRELA may be handled differently depending on overall medical conditions, including kidney or liver problems.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
For severe diarrhea: suspend dosing and rehydrate the patient (specific management step).
Importance:
Moderate
No support in the provided claims for contraindications (e.g., mechanical GI obstruction; contraindication in patients <6 years).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported missed-dose and meal/timing instructions could affect safe use; the claim about dose changes/stopping therapy for side effects is not fully aligned with label wording for severe diarrhea management (suspend dosing and rehydrate). Core dose and overdose risk statement align.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several administration and missed-dose instructions plus kidney/liver dosing considerations are not supported by the supplied label excerpts.
Suggested Improvement
Restrict statements to label-supported dosing (50 mg orally twice daily) and label-supported severe diarrhea management (suspend dosing and rehydrate). Remove or revise meal/timing, missed-dose handling, and kidney/liver dosing claims unless supported by the full label text.